Treatments for MDS and Secondary AML - Part 2, High-Risk @AAMDSIF

Treatments for MDS and Secondary AML - Part 2, High-Risk @AAMDSIF

Uploaded April 2024 | Updated September 2026, 19 hours ago

From the 2024 International Bone Marrow Failure Disease Scientific Symposium: Dr. Andrew Brunner and Dr. Jacqueline Garcia discuss research presentations

#mdsnews #bloodcancer #marrowfailure #aml

Treatments for MDS and Secondary AML - Part 2, High-Risk

Learn about newly approved oral medication for patients with PNH

Understanding Low Risk MDS 2021 Winter Patient Family Conference

High-Risk MDS and Secondary AML with Hetty Carraway, MD, MBA and Amer Zeidan, MD

What is the IPSS-M for MDS? With Dr. Gail Roboz

Mucocutaneous GVHD

MDS and Non-Transplant Therapies from the Patient and Family Conference in Salt Lake City, UT, 2023

Cytopenia Management of Low Risk MDS, or Myelodysplastic Syndromes

Athletic Service Member Conquers Aplastic Anemia and MDS with Transplant

AAMDSIF 40th Anniversary Summit: The Future of Clinical Trials Panel Discussion

Treatment Decisions in Chronic GVHD

CLONALITY IN ACQUIRED BONE MARROW FAILURE, PNH, VEXAS

Treatments for MDS and Secondary AML - Part 2, High-Risk